Access my individual Investor account information, including account balances, transaction history and tax forms.
Access AccountBy clicking "Proceed", you will be directed to a server of an unaffiliated company who is a service provider of Voya Investment Management. By clicking the button, you will leave this site and proceed to the selected site. Voya Investment Management, its subsidiaries or affiliates, do not guarantee the accuracy or timeliness of the information contained on the website.
ProceedSign up for the convenience of paperless communications
Go NowYou will be notified by e-mail when these communications become available on the Internet. Printed copies of these communications may still be requested. Documents that are not available on the Internet will continue to be sent to you by mail.
If you have any questions about our e-Delivery program, please call (800) 992-0180.
For access to advisor-only content, including the exclusive Retirement University blog, learning modules and tools
Log In
Market sentiment is looking ahead to the end of the coronavirus pandemic, probably in the first half of 2021, when an effective vaccine is widely distributed. An end date on the horizon is certainly a good thing for stocks.
We expect a big bounce in 3Q20 global growth, but because an effective COVID-19 vaccine is unlikely until mid- to late-2021, further gains in 4Q20 and 1H21 will prove more difficult.
As U.S. COVID-19 cases increase, so does the risk that economic recovery decelerates. We think policy makers will do what it takes to sustain the recovery, and therefore continue to prefer U.S. equities over bonds.
Upbeat retail sales pushed U.S. stocks into positive territory on Friday, despite other economic data that pointed to slowing momentum.
Global stocks posted strong weekly gains as markets processed signs that another round of U.S. coronavirus stimulus might be within reach. All 11 S&P 500 sectors posted gains.
Market sentiment is looking ahead to the end of the coronavirus pandemic, probably in the first half of 2021, when an effective vaccine is widely distributed. An end date on the horizon is certainly a good thing for stocks.
We expect a big bounce in 3Q20 global growth, but because an effective COVID-19 vaccine is unlikely until mid- to late-2021, further gains in 4Q20 and 1H21 will prove more difficult.
As U.S. COVID-19 cases increase, so does the risk that economic recovery decelerates. We think policy makers will do what it takes to sustain the recovery, and therefore continue to prefer U.S. equities over bonds.
Despite our expectations for a dreadful drop in 2Q20 output, we believe a recovery will commence in 3Q20 and lead to a meaningful acceleration beginning in 2021. Accordingly, stocks still look more attractive to us than bonds.
We are still overweight U.S. large caps, believing winners will win until a broad-based economic recovery takes hold. Our preference for investment grade U.S. bonds remains; also, we now see opportunities among high yield bonds.
Recent market dislocation has created an opportunity to reposition portfolios to capitalize on the new business cycle.
We consider the coronavirus outbreak a temporary shock, inducing a technical recession but not fundamentally impairing productive capacity. Considering this and an expanded equity risk premium, we see stocks as more attractive than bonds.
We continue to believe the economies of China, Europe and Japan are in the process of reaccelerating. Although the coronavirus alters the near-term outlook for Asia, underlying market fundamentals historically have prevailed once an outbreak subsides.